Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Oksana Gurtovaya"'
Autor:
Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objectives Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the pre
Externí odkaz:
https://doaj.org/article/c9f79c28f9ee49ac9315662dd767f3a8
Autor:
Elizabeth, Price, Michele, Bombardieri, Alan, Kivitz, Franziska, Matzkies, Oksana, Gurtovaya, Alena, Pechonkina, Wendy, Jiang, Bryan, Downie, Anubhav, Mathur, Afsaneh, Mozaffarian, Neelufar, Mozaffarian, J Eric, Gottenberg
Publikováno v:
Rheumatology. 61:4797-4808
Objective The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. Methods This multicentre, double-blind study randomized patients with active primary or secondary SS [
Autor:
Alena Pechonkina, Iyabode Tiamiyu, Zahi Touma, Daniel J. Wallace, Michael Robern, Victoria P. Werth, Franziska Matzkies, Roy Fleischmann, Oksana Gurtovaya, Bryan R. Downie, Afsaneh Mozaffarian
Publikováno v:
Rheumatology (Oxford, England). 61(6)
Objectives To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE). Methods This was a phase 2, randomized, double-blind, placebo-c
Autor:
Bruce C. Marshall, Matthew McKevitt, Lisa Saiman, Pradeep K. Singh, Claire Keating, Mark Bresnik, Oksana Gurtovaya, Jonathan B. Zuckerman
Publikováno v:
Antimicrobial Agents and Chemotherapy
The approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect the susceptibility profiles of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients. This 5-yea
Autor:
Paolo Ghia, Oksana Gurtovaya, Guan Xing, Jacqueline C. Barrientos, John M. Pagel, Bianca Ruzicka, Peter Hillmen, Jeff P. Sharman, Gilles Salles, Pankaj Bhargava, Stephan Stilgenbauer
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c743f20a2697821297bba356ffbcb373
Autor:
Mark C. Genovese, Uptal D. Patel, Panduranga Rao, James Tumlin, Yashaar Chaichian, Matthew C. Baker, Vimal K. Derebail, S. Sam Lim, Hooman Hajian, W. Winn Chatham, Oksana Gurtovaya, Michael R. Bubb
Publikováno v:
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, Vol 6, Iss 3 (2020)
ObjectivesPatients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the pref
Autor:
Gary S. Sachs, Phillip B. Chappell, Douglas Vanderburg, Oksana Gurtovaya, Kathleen S. Ice, Bryce Kasuba, Jeffrey H. Schwartz
Publikováno v:
The Journal of clinical psychiatry. 72(10)
Objective To assess efficacy and safety of adjunctive ziprasidone in subjects with bipolar depression treated with lithium, lamotrigine, or valproate. Method 298 adult outpatients with bipolar I disorder (DSM-IV criteria) were randomized to receive z
Publikováno v:
The Journal of General Physiology
Both intracellular calcium and transmembrane voltage cause inactivation, or spontaneous closure, of L-type (CaV1.2) calcium channels. Here we show that long-lasting elevations of intracellular calcium to the concentrations that are expected to be nea
Autor:
Andrew D. Zelenetz, Oksana Gurtovaya, Gilles Salles, John M. Pagel, Jeff Porter Sharman, Paolo Ghia, Jacqueline C. Barrientos, Stephan Stilgenbauer, Betsy Philip, Yeonhee Kim
Publikováno v:
Publons
8563 Background: IDELA, a selective oral PI3Kδ inhibitor, is approved for use in relapsed CLL (in combination with rituximab [R]) and iNHL (as monotherapy). Both diseases occur mainly in the elderl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::744d97575680cdf457e374be7e2ddfa6
https://publons.com/publon/26048723/
https://publons.com/publon/26048723/